Trial · NCT02075255
Results by group157
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 157
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control | Benralizumab 30 mg q.4 Weeks | 75.00 | 95% Confidence Interval 50.00 to 83.30 | Percent | |
| Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control | Benralizumab 30 mg q.8 Weeks | 75.00 | 95% Confidence Interval 60.00 to 87.50 | Percent | |
| Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control | Placebo | 25.00 | 95% Confidence Interval 0.00 to 33.30 | Percent | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Benralizumab 30 mg q.4 Weeks | >=90% reduction | 24 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Benralizumab 30 mg q.8 Weeks | >=90% reduction | 27 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Placebo | >=90% reduction | 9 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Benralizumab 30 mg q.4 Weeks | >=75% reduction | 38 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Benralizumab 30 mg q.8 Weeks | >=75% reduction | 37 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Placebo | >=75% reduction | 15 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Benralizumab 30 mg q.4 Weeks | >=50% reduction | 48 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Benralizumab 30 mg q.8 Weeks | >=50% reduction | 48 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Placebo | >=50% reduction | 28 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Benralizumab 30 mg q.4 Weeks | >0% reduction | 55 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Benralizumab 30 mg q.8 Weeks | >0% reduction | 58 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Placebo | >0% reduction | 40 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Benralizumab 30 mg q.4 Weeks | No change or any increase | 17 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Benralizumab 30 mg q.8 Weeks | No change or any increase | 15 | Participants | |
| Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Placebo | No change or any increase | 35 | Participants | |
| Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils >=300/uL | Benralizumab 30 mg q.4 Weeks | 75.00 | 95% Confidence Interval 60.00 to 100.00 | Percent | |
| Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils >=300/uL | Benralizumab 30 mg q.8 Weeks | 75.00 | 95% Confidence Interval 60.00 to 91.70 | Percent |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02075255/results